Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis

Radiology

Volumn 252, Issue 2, 2009, Pages 534-543

  Farrell, Philip M ^a   Collins, Jannette ^b   Broderick, Lynn S ^b   Rock, Michael J ^a   Li, Zhanhai ^a   Kosorok, Michael R ^c   Laxova, Anita ^a   Gershan, William M ^d   Brody, Alan S ^e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c IL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; CHILD; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RISK FACTOR; THORAX; COMORBIDITY; CROSS-SECTIONAL STUDY; PREVALENCE; RADIOGRAPHY; RISK ASSESSMENT; STATISTICS; UNITED STATES;

ADOLESCENT; BRONCHIECTASIS; CHILD; COMORBIDITY; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PREVALENCE; PSEUDOMONAS INFECTIONS; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 70249089074     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2522081882     Document Type: Article

References (55)

1. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27(1):158-163. (Pubitemid 28334435)
2. Farrell PM, Li Z, Kosorok MR, et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 2003;168(9):1100-1108. (Pubitemid 37338940)
3. Farrell PM, Li Z, Kosorok MR, et al. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003;36(3):230-240. (Pubitemid 37055971)
4. Brody AS, Tiddens HA, Castile RG, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 2005;172(10):1246-1252. (Pubitemid 43076562)
5. Brody AS, Sucharew H, Campbell JD, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005;172(9):1128-1132. (Pubitemid 43066648)
6. Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9(8):1601-1604. (Pubitemid 26271139)
7. Brody AS, Klein JS, Molina PL, et al. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145(1):32-38. (Pubitemid 38962449)
8. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61(5):414-418. (Pubitemid 43723325)
9. Miszkiel KA, Wells AU, Rubens MB, et al. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 1997;52(3):260-264.
10. Sheehan RE, Wells AU, Copley SJ, et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002;20(3):581-587.
11. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23(1):93-97. (Pubitemid 38088503)
12. Fost N, Farrell PM. A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: a unique ethical dilemma. Clin Res 1989;37(3):495-500. (Pubitemid 19214804)
13. Farrell PM. Improving the health of patients with cystic fibrosis through newborn screening. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr 2000;47:79-115.
14. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32(4):277-287. (Pubitemid 32938876)
15. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293(5):581-588. (Pubitemid 40171240)
16. Brody AS, Kosorok MR, Li Z, et al. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J Thorac Imaging 2006;21(1):14-21.
17. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125(2):509-521. (Pubitemid 38223630)
18. Brody AS, Molina PL, Klein JS, et al. Highresolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. Pediatr Radiol 1999;29(10):731-735.
19. Braun AT, Farrell PM, Ferec C, et al. Cystic fibrosis mutations and genotype-pulmonary phenotype analysis. J Cyst Fibros 2006;5(1):33-41. (Pubitemid 43137159)
20. Wang X, Dockery DW, Wypij D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15(2):75-88.
21. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358(9286):983-984. (Pubitemid 32913526)
22. Sokol PA, Luan MZ, Storey DG, et al. Genetic rearrangement associated with in vivo mucoid conversion of Pseudomonas aeruginosa PAO is due to insertion elements. J Bacteriol 1994;176(3):553-562.
23. Cystic Fibrosis Foundation. Cystic fibrosis patient registry 2007 annual data report. Bethesda, Md: Cystic Fibrosis Foundation, 2008.
24. Schaedel C, de Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33(6):483-491. (Pubitemid 34547870)
25. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138(5):699-704. (Pubitemid 32417671)
26. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34(2):91-100. (Pubitemid 34809519)
27. de Jong PA, Ottink MD, Robben SG, et al. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004;231(2):434-439.
28. Puderbach M, Eichinger M, Haeselbarth J, et al. Assessment of morphological MRI for pulmonary changes in cystic fibrosis (CF) patients: comparison to thin-section CT and chest x-ray. Invest Radiol 2007;42(10):715-725. (Pubitemid 351325904)
29. Paterson A, Frush DP. Dose reduction in paediatric MDCT: general principles. Clin Radiol 2007;62(6):507-517. (Pubitemid 46630119)
30. Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000;29(3):182-187. (Pubitemid 30141794)
31. Valery PC, Torzillo PJ, Mulholland K, et al. Hospital-based case-control study of bronchiectasis in indigenous children in Central Australia. Pediatr Infect Dis J 2004;23(10):902-908. (Pubitemid 40812775)
32. Barker AF, Bardana EJ Jr. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 1988;137(4):969-978.
33. Nicotra MB. Bronchiectasis. Semin Respir Infect 1994;9(1):31-40.
34. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8):918-951. (Pubitemid 37267172)
35. Baltimore RS, Christie CD, Smith GJ. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis: implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis 1989;140(6):1650-1661.
36. Corech R, Rao A, Laxova A, et al. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J Clin Microbiol 2005;43(8):3956-3962. (Pubitemid 41129686)
37. Sadikot RT, Blackwell TS, Christman JW, et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005;171(11):1209-1223. (Pubitemid 40740727)
38. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 2002;34(3):232-236. (Pubitemid 34971079)
39. Hoiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatr Drugs 2000;2(6):451-463.
40. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144(2):154-161. (Pubitemid 38869388)
41. Parad RB, Gerard CJ, Zurakowski D, et al. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999;67(9):4744-4750. (Pubitemid 29400459)
42. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53(RR-13):1-36.
43. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167(6):841-849. (Pubitemid 36801771)
44. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29(3):177-181. (Pubitemid 30141793)
45. Farrell PM, Shen G, Splaingard M, et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997; 100(5):E2. doi:10.1542/peds.100.5.e2. Accessed September 2008.
46. Griffiths AL, Jamsen K, Carlin JB, et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 2005;171(9):1020-1025. (Pubitemid 40616952)
47. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166(7):983-987. (Pubitemid 35193230)
48. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003;31(3 suppl):S1-S62. (Pubitemid 36798093)
49. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28(5):321-328. (Pubitemid 29523443)
50. West SE, Zeng L, Lee BL, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287(22):2958-2967. (Pubitemid 34619999)
51. Kappler M, Kraxner A, Reinhardt D, et al. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 2006;61(8):684-688. (Pubitemid 44211775)
52. Farrell PM, Govan JR. Pseudomonas serology: confusion, controversy, and challenges. Thorax 2006;61(8):645-647.
53. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25(2):88-92. (Pubitemid 28110583)
54. Munck A, Bonacorsi S, Mariani-Kurkdjian P, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001;32(4):288-292. (Pubitemid 32938877)
55. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42(7):610-623. (Pubitemid 47022973)